NeOnc Technologies Holdings, Inc. disclosed that it completed a private placement financing during the first quarter of 2026, raising approximately $13 million in gross proceeds. The capital raise is intended to strengthen the company’s balance sheet, repay short‑term convertible debt, and fund ongoing clinical development and operating expenses.
The financing provides a modest liquidity cushion for a company that reported a $97.23 million accumulated deficit as of September 30 2025 and $1.51 million in cash. The deficit has expanded from $50.6 million at the end of 2024 to $112.7 million at the end of 2025, underscoring the high burn associated with clinical‑stage development. The cash balance, while modest, is sufficient to cover short‑term obligations until the next funding round.
Proceeds will be used to repay short‑term convertible debt and to support the development of the company’s lead candidates, NEO100 and NEO212, which are designed to bypass the blood‑brain barrier and treat central nervous system cancers. While the exact allocation to each program is not disclosed, the funding is expected to cover pre‑clinical studies, regulatory filings, and early‑phase clinical trials.
Chief Financial Officer Keithly Garnett noted that the company has advanced its clinical programs while completing its transition to a public company, and that the new capital will be deployed toward value‑creating milestones. Chairman and CEO Amir Heshmatpour, who purchased approximately $300,000 of company stock on the same day, added that the financing will accelerate the clinical pipeline and reinforce confidence in the company’s strategy.
The private placement is a critical step for NeOnc, which has reported a net loss of $62.1 million for 2025 and continues to rely on external financing to fund operations. The $13 million raise, while modest relative to the accumulated deficit, provides a short‑term buffer that can delay the need for additional debt or equity offerings. The company’s continued reliance on capital raises highlights the high risk profile of its business model, but the investment in NEO100 and NEO212 also represents a potential high‑value opportunity if the candidates achieve regulatory milestones.
NeOnc has a history of raising capital, including an $18.5 million financing in June 2024 and a $10 million equity round in February 2023. These previous raises have helped sustain the company’s clinical pipeline, but the cumulative effect has been an expanding accumulated deficit and a persistent need for liquidity. The latest financing continues that pattern, reinforcing the company’s strategy of incremental capital infusions to support its long‑term development goals.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.